- Home
- CLDI vs NEUP Comparison
CLDI vs NEUP Comparison
Compare CLDI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- NEUP
- Stock Information
- Founded
- CLDI 2014
- NEUP 1996
- Country
- CLDI United States
- NEUP United States
- Employees
- CLDI N/A
- NEUP N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- NEUP
- Sector
- CLDI Health Care
- NEUP
- Exchange
- CLDI Nasdaq
- NEUP Nasdaq
- Market Cap
- CLDI 12.0M
- NEUP 12.7M
- IPO Year
- CLDI N/A
- NEUP N/A
- Fundamental
- Price
- CLDI $0.36
- NEUP $6.87
- Analyst Decision
- CLDI Strong Buy
- NEUP Strong Buy
- Analyst Count
- CLDI 1
- NEUP 1
- Target Price
- CLDI $10.00
- NEUP $21.00
- AVG Volume (30 Days)
- CLDI 456.3K
- NEUP 29.5K
- Earning Date
- CLDI 05-14-2025
- NEUP 06-17-2025
- Dividend Yield
- CLDI N/A
- NEUP N/A
- EPS Growth
- CLDI N/A
- NEUP N/A
- EPS
- CLDI N/A
- NEUP 0.00
- Revenue
- CLDI N/A
- NEUP $15,662,715.00
- Revenue This Year
- CLDI N/A
- NEUP N/A
- Revenue Next Year
- CLDI N/A
- NEUP N/A
- P/E Ratio
- CLDI N/A
- NEUP $4,008.24
- Revenue Growth
- CLDI N/A
- NEUP N/A
- 52 Week Low
- CLDI $0.34
- NEUP $2.90
- 52 Week High
- CLDI $3.89
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- CLDI 34.85
- NEUP N/A
- Support Level
- CLDI $0.34
- NEUP N/A
- Resistance Level
- CLDI $0.39
- NEUP N/A
- Average True Range (ATR)
- CLDI 0.04
- NEUP 0.00
- MACD
- CLDI 0.00
- NEUP 0.00
- Stochastic Oscillator
- CLDI 15.45
- NEUP 0.00
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.